[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aging-well\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aging-well":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,70,97,124,146,175,201,229],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":40,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100636291","100-year-human-aging-study-100636291",false,"NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",true,"ALL","18 Years",{"count":20,"type":21},1000000,"ESTIMATED","OBSERVATIONAL","The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Aging","Aging Well","All-Cause Mortality","Mortality","Metabolic Syndrome","Cardiovascular Diseases","Cognitive Dysfunction","Musculoskeletal Diseases","Neoplasms","Frailty","Activities of Daily Living","Health-Related Quality of Life","Disability Physical","Neuro-Degenerative Disease","Dementia",[41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56],"Longevity","Cardiopulmonary Exercise Testing","Body Composition","Preventive Medicine","Surrogate Endpoint Validation","Mortality Prediction","Functional Decline","Healthspan","Life Expectancy","Biological Aging","Preventive Screening","Longitudinal Cohort","Biomarker Validation","Human Performance","Population Health","Centenarian","RECRUITING","2026-06-09",{"date":60,"type":61},"2026-06-11","ACTUAL",{"date":63,"type":61},"2025-02-09",{"date":65,"type":21},"2099-12-31",{"name":67,"class":68},"Longevity Metrics, Inc.","INDUSTRY",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":16,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":69},"100636944","adjuvant-nitrate-to-boost-exercise-induced-health-benefits-in-older-adults-100636944","NCT07572266","Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults","BOOST-X","Inclusion Criteria:\n\n1. Male or female aged 60 years or older\n2. Free of chronic disease or disorder that would preclude full participation or have the potential to confound results\n3. No structured exercise program (2 or more bouts\u002Fwk) within previous 12 months\n4. Cognitively capable of providing informed consent\n\nExclusion Criteria:\n\n1. BMI ≥ 30.0 kg\u002Fm2\n2. Neurodegenerative disease\n3. Neuromuscular, musculoskeletal or orthopedic disorder or condition that would limit ability to perform the exercise prescription and\u002For physical performance testing\n4. Diagnosed orthostatic hypotension, i.e., a drop in systolic blood pressure of at least 20 mmHg or a drop in diastolic blood pressure of at least 10 mmHg within three minutes of standing up from a sitting or lying position.\n5. Resting blood pressure \\\u003C90\u002F60 mmHg or \\>160\u002F95 mmHg\n6. Uncontrolled hypertension\n7. Any current cardiovascular disease or cardiopulmonary instability\n8. Recent cardiovascular event or procedure within the preceding 6 months\n\n   1. If valve replacement has been performed, patient may not be enrolled for 12 months after the procedure\n   2. Any mechanical valve replacement that requires continuous warfarin anti-coagulation\n9. Anemia: Hgb \\\u003C11.0 (♂),10.0 (♂) gm\u002Fdl\n10. Diabetes with HgbA1c \\>7.0% or fasting blood glucose ≥ 130 mg\u002Fdl\n11. Liver disease with ALT \\> 52 U\u002Fl)\n12. Chronic kidney disease (eGFR \\\u003C 45)\n13. Any current infectious disease\n14. Any other disease or disorder that could influence exercise response, preclude full participation or have the potential to confound results (e.g., chronic lung disease, cognitive impairment, current cancer diagnosis or within 2 yr remission, cerebrovascular disease, pain)\n15. Life expectancy \\\u003C 1 year Medications \u002F lifestyle\n16. Insulin sensitizing\u002Fblood glucose lowering agents such as metformin\n17. Currently on or have used GLP-1 agonist or other metabolic \u002F weight loss drug in previous 12 weeks\n18. Use of nitrate medications\n19. High dose statin (≥40 mg\u002Fd simvastatin equivalence)\n20. Chronic corticosteroids\n21. Testosterone or other anabolic\u002Fandrogenic hormone therapy\n22. Lidocaine allergy\n23. Regular tobacco use and\u002For vaping \\> 1\u002Fwk\n24. Use of cannabis \\> 1\u002Fwk\n25. Excessive alcohol consumption (3 drinks\u002Fd or 7 drinks\u002Fwk for females; 4 drinks\u002Fd or 14 drinks\u002Fwk for males)\n26. Use of illicit drugs (e.g., cocaine, opioids)\n27. Unable to commit to \\~4 months required to complete the study","60 Years",{"count":79,"type":21},226,"INTERVENTIONAL",[82],"NA","Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments to compromise intrinsic capacity and healthspan. Exercise is the only multipotent treatment with promise to mitigate many of the aging hallmarks, but there is substantial variability in individual exercise responsiveness. Thus, the investigators approach to boosting exercise responsiveness in aging is to combine an exercise training prescription containing both endurance and resistance training (in alignment with DHHS guidelines) with a nitrate-enriched dietary supplement to augment the cellular, tissue, and systemic adaptations that induce myriad health benefits of exercise in older adults.",[25,26,85],"Healthy Aging","NOT_YET_RECRUITING","2026-04-30",{"date":89,"type":61},"2026-05-07",{"date":91,"type":21},"2026-05",{"date":93,"type":21},"2031-05",{"name":95,"class":96},"Florida Institute for Human and Machine Cognition","OTHER",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":80,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":69},"100509222","transcranial-pulse-stimulation-of-the-brain-100509222","NCT05910619","Transcranial Pulse Stimulation of the Brain","Transcranial Pulse Stimulation of the Brain in Older Adults With and Without Mild Dementia","Inclusion Criteria:\n\n* Men and women\n* Age: 65 to 84 years\n* English speaking\n* Physically mobile with no history of balance difficulties or major falls\n* For the typically-aging older adult group, phone screening performance on the TICS must be greater than or equal to 33 points, and cognitive performance of 26 points or greater on the MoCA and a Sum of Boxes score of 0 on the Clinical Dementia Rating scale administered to the participant's informant at the initial visit\n* For the Mild dementia group, phone screening performance on the TICS must be between 21 and 32 points, and subsequent cognitive performance of on the MoCA must be \\\u003C23 with a CDR Sum of Boxes score between 4.5 and 9.0 as administered to the participants known informant at the initial visit.\n\nExclusion Criteria:\n\n* Neurological disorders unrelated to dementia \u002F AD (e.g., Parkinson's disease, stroke, seizures, traumatic brain injury)\n* Evidence of greater-than-mild dementia\u002FAD (based on informant CDR Sum of Boxes score greater than 9.0 or MoCA \\\u003C10)\n* Past opportunistic brain infection\n* Major psychiatric illness (schizophrenia, intractable affective disorder, current substance dependence diagnosis or severe major depression and\u002For suicidality) or any history of agitation and\u002For delirium\n* Unstable (e.g., cancer other than basal cell skin) and chronic (e.g., diabetes mellitus) medical conditions\n* MRI contraindications (e.g., pregnancy, claustrophobia, metal implants that are contraindicated for MRI and TPS)\n* Physical impairment precluding motor response or lying still for one hour and inability to walk two blocks without stopping or without balance difficulties\n* Drug exclusions include those medications that are known to have cognitively sedating or altering effects as well medications with a strong anticholinergic burden or CNS effects. Participants should be stable on any recently altered medications\u002Fdosages for at least four weeks prior to beginning the study. Medications will be reviewed during the interview for the purpose of identification of contraindicated pharmacological agents with common cognitive side-effects\n* Other history of medical conditions that may increase risk of cerebrovascular events, including prior heart attack, cardiac arrhythmia such as atrial fibrillation\n* Hearing or vision deficits that will not allow for reliable standardized cognitive assessment; i.e. colorblindness, inability to hear through headphones (with or without hearing aids), macular degeneration or other significant diseases that cause severe loss of vision. If vision is corrected with lenses to appropriate levels, then participant will be eligible\n* Left-handedness and ambidextrousness, as these individuals have a higher percentage rate of atypical functional lateralization for brain functions, which would significantly interfere with interpretability of brain data\n* Hemophilia or other blood clotting disorders or thrombosis\n* Corticosteroid treatment within the last six weeks before the first treatment","65 Years","84 Years",{"count":107,"type":21},20,[82],"This study will investigate transcranial pulse stimulation (TPS) as a method of enhancing cognitive and neural function. The study team will apply this low intensity, magnetically pulse technology to key brain regions in a randomized, sham-controlled trial (RCT). The study will determine the magnitude of changes in cognitive function and brain function and structure between a pre- and post-stimulation among 10 typically-aging older adults and 10 patients with mild dementia.",[111,26],"Mild Dementia",[111,113,114],"Typical Aging","Transcranial Pulse Stimulation","2026-04-28",{"date":117,"type":61},"2026-04-29",{"date":119,"type":61},"2024-02-16",{"date":121,"type":21},"2026-12-07",{"name":123,"class":96},"University of Florida",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":16,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":80,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},"100555061","multidimensional-predictive-modeling-to-understand-mechanisms-of-exercise-response-heterogeneity-in-older-adults-m3ax-100555061","NCT06507189","Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)","Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults","M3AX","Inclusion Criteria:\n\n1. Male or female aged 60 or above\n2. Free of chronic disease\n3. No structured exercise program (2 or more bouts\u002Fwk) within previous 12 months\n4. Cognitively capable of providing informed consent\n\nExclusion Criteria:\n\n1. Neuromuscular or musculoskeletal disorder that would limit ability to perform the exercise and\u002For testing bouts\n2. Cardiopulmonary disorders or reduced breathing capacity\n3. Metabolic diseases including markers of liver disease (ALT \\> 52 U\u002Fl) and type 2 diabetes (HbA1C ≥ 6.5, fasting blood glucose ≥ 126 mg\u002Fdl)\n4. Any other disease or disorder that would influence exercise response (e.g., chronic kidney disease, dementia, current cancer diagnosis or within 2 yr remission, cerebrovascular disease)\n5. History of chemotherapy within 5 years\n6. Any current infectious disease\n7. Life expectancy \\\u003C 1 year\n8. Insulin sensitizing\u002Fblood glucose lowering agents such as metformin\n9. High dose statin (dose equivalent to ≥40 mg\u002Fd simvastatin)\n10. Lidocaine allergy\n11. Regular tobacco use and\u002For vaping\n12. Excessive alcohol consumption (3 drinks\u002Fd or 7 drinks\u002Fwk for females; 4 drinks\u002Fd or 14 drinks\u002Fwk for males)\n13. BMI \\\u003C 35.0 kg\u002Fm2\n14. Unable to commit to \\~6 months required to complete the study",{"count":133,"type":21},250,[82],"Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments that compromise healthspan and quality of life. Exercise is a multipotent treatment with promise to mitigate most aging hallmarks, but there is substantial variability in exercisƒe responsiveness. Combining endurance and resistance training in alignment with public health guidelines will be used to better understand variable exercise responsiveness in older adults with the ultimate goal of improving each older adult's capacity to attain the many health benefits of exercise.",[25,26],"2026-04-17",{"date":139,"type":61},"2026-04-22",{"date":141,"type":61},"2025-01-27",{"date":143,"type":21},"2029-08-31",{"name":95,"class":96},2,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":16,"sex":17,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":80,"phases":157,"briefSummary":158,"conditions":159,"keywords":162,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":69},"100618629","emotional-well-being-and-measures-of-healthy-aging-100618629","NCT07334106","Emotional Well-being and Measures of Healthy Aging","Emotional Well-being and Biomarkers of Healthy Aging","Inclusion Criteria:\n\n* Age 40-70\n* Speaks and reads English\n* Able to access the online platform through their phone, a public device (i.e., at the library) or at home.\n* Lives in the Chicagoland area\n* Willing\u002Fable to travel to the Human Longevity Lab for in-person visits\n\nExclusion Criteria:\n\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Pregnant women\n* Prisoners\n* Vulnerable Populations\n* Pre-existing heart disease (prevalent coronary heart and cerebrovascular disease or heart failure)\n* Type 2 diabetes\n* Severe psychiatric illness","40 Years","70 Years",{"count":156,"type":21},80,[82],"This randomized control study is designed to understand the role of a positive psychology intervention (PARK: Positive Affect Regulation sKills) in biological aging and well-being. PARK provides a series of positive emotion skills in a self-guided online format, making the program accessible and convenient.\n\nOur main aims are:\n\nAim 1: To explore the effects of PARK on psychological well-being (e.g., depression, anxiety, positive affect).\n\nAim 2: To explore the effects of PARK on biological age as defined by DNA methylation (DNAm) GrimAge and electrocardiogram-age (ECG-age), as well as physiological well-being in adults (e.g., cardiovascular, endocrine, musculoskeletal functioning, etc.).",[25,160,26,161],"Aging, Healthy","Aging, Biological",[25,163,164,26,165],"Resilience, Psychological","Psychological Well-Being","Internet-Based Intervention","2026-01-02",{"date":168,"type":61},"2026-01-12",{"date":170,"type":61},"2025-09-01",{"date":172,"type":21},"2028-08",{"name":174,"class":96},"Northwestern University",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":182,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":80,"phases":185,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":69},"100509999","healthy-lifetime---phase-2-100509999","NCT05920733","Healthy Lifetime - Phase 2","Healthy Lifetime - Sustainability and Quality Study - PHASE 2","Inclusion Criteria:\n\n* Be able to read, speak English and hear - but may use glasses or hearing aids, if needed;\n* Be able to tell us their age, their date of birth, address, and phone number, as well as write down and explain their health problems;\n* Have their own computer or iPad (Tablet) with an Internet connection, a working camera and microphone. and\n* Be able to use their computer\u002Ftablet to connect to video chat sessions like Zoom in a private space in their home or a private room.\n\nExclusion Criteria:\n\n* People who, in the last month, have used the Emergency Room (ER) or stayed in the hospital.\n* Are not verified users of Medicaid Home Help services \\[we will check with the Michigan Department of Health and Human Service to verify that you receive these services using your name, date of birth, and Medicaid identification number\\];\n* Have a new major health problem that they are seeing a doctor about more than once per month;\n* Have been told their illness is not curable;\n* Cannot remember their name, date of birth or their health problems;\n* Cannot use glasses or a hearing aid to see or hear well enough to read materials on the computer or talk to the nurse easily; and,\n* Do not have, or cannot use, a computer, iPad or other device with the Internet at home to use Zoom (e.g., internet streaming).","30 Years",{"count":184,"type":21},120,[82],"HealthyLifetime (HL) is a person-centered program that enables older adults to maximize health and optimize functioning - the necessary requisite to successfully remaining independent in their preferred home setting as long as possible, i.e., to age in place.",[26],[189,190,191],"nurse coaching","motivational interviewing","aging","2025-10-11",{"date":194,"type":61},"2025-10-15",{"date":196,"type":61},"2023-07-05",{"date":198,"type":21},"2026-10-01",{"name":200,"class":96},"University of Michigan",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":207,"minAge":208,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":80,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":69},"100556589","effect-of-aromatherapy-for-facial-aesthetics-in-alleviating-signs-of-aging-pilot-study-100556589","NCT06527066","Effect of Aromatherapy for Facial Aesthetics in Alleviating Signs of Aging: Pilot Study","Inclusion Criteria:\n\n* cisgender women;\n* 45 to 55 years old;\n* classification of II and III on the Glogau Scale;\n* agree to participate in the research considering the conditions and stages of the study protocol;\n* do not present adverse reactions to the topical use of the essential oil and its carrier base.\n\nExclusion Criteria:\n\n* pregnant women;\n* breastfeeding women;\n* people diagnosed with neurological, serious dermatological diseases and others serious illnesses;\n* people with facial injuries;\n* severe allergies or occurrence of serious adverse events due to the use of cosmetics and\u002For cosmeceuticals in the past;\n* participants who present an allergic reaction during the allergenicity test and\u002For during the study;\n* those who underwent aesthetic facial procedures with fillers (except lip fillers) and botulinum toxin up to 6 months before the start of the protocol, PDO threads up to 3 months before, and chemical, mechanical and laser peelings, as well as microneedling, up to 1 month before the beginning of participation;\n* use of cosmeceuticals seven to ten days before participating in the study, as well as during it, with only the use of photoprotector being permitted and recommended;\n* people who have undergone facial aesthetic surgery, except rhinoplasty.","FEMALE","45 Years","55 Years",{"count":211,"type":21},38,[82],"Introduction: aesthetics is one of the specialties for professional nurses and presents a dialogue with Aromatherapy, a practice that uses essential oils (EO) from aromatic plants, being one of the most used integrative therapies for beauty care, youth and well-being. EOs are volatile compounds extracted from the most diverse parts of plants and some, such as geranium (Pelargonium graveolens), have antioxidant action, acting in the regeneration and maintenance of skin tissue, becoming a potential ally in the prevention and\u002For treatment of wrinkles, as well as general skin aging. Several anti-aging strategies are available, but consumers in aesthetics have increasingly prioritized their health and well-being, desiring non-invasive products and treatments, of natural origin, that guarantee safety and effectiveness. Objective: to evaluate the effect of Aromatherapy in alleviating the signs of aging on the facial skin of women, through a protocol of topical facial application, twice a day, with geranium EO (Pelargonium graveolens) diluted at 1% in Biocompatible Serum Gel All.me Beauty. Method: pilot study with a Randomized Clinical Trial (RCT) design, using the Consolidated Standards of Reporting Trials (CONSORT) as a reference, in its extension to randomized pilot and feasibility trials, double-blind (researcher and statistician). The sample will consist of 38 participants, estimating a loss of 10% throughout the study, who will be randomized between the Placebo Group (G1), whose treatment will be with pure use of the carrier base, and Intervention Group (G2), whose treatment will be with geranium EO diluted to 1% in All.me Beauty® Biocompatible Serum Gel. Participants must perform self-application at home, following a determined protocol and the intervention will respect a standard, in accordance with the guidelines of the manufacturer of the equipment used to measure the participants\\' progress in terms of wrinkles, hydration and elasticity of the facial skin, these being: Visioscan ® VC 20 Plus, Corneometer® CM 825 and Cutometer® Dual MPA 580.",[26],[216,217,218,219],"Aesthetics","Complementary Therapies","Aromatherapy","Nursing","2025-02-04",{"date":222,"type":61},"2025-02-07",{"date":224,"type":61},"2024-09-16",{"date":226,"type":21},"2025-07",{"name":228,"class":96},"University of Sao Paulo",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":16,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":239,"conditions":240,"keywords":246,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":69},"100402297","prevalence-determinants-and-natural-history-of-frailty-and-pre-frailty-in-elderly-people-100402297","NCT04518423","Prevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People","Prevalence, Determinants and Natural History of Frailty and Pre-frailty in People Over the Age of 65 Years in a Prospective 5-year Observation","FRAILPOL","Inclusion Criteria:\n\n* Community dwelling elderly individuals over the age of 65 years who get around by themselves.\n\nExclusion Criteria:\n\n* Institutionalization\n* Inability to move around\n* Terminal diseases with an anticipated survival of less than 1 year.",{"count":238,"type":21},1093,"Frailty syndrome (i.e. frailty) is a geriatric syndrome which relies on the reduction of multisystem reserve capacity. Frail people have a lower potential to respond to external stressors and various life incidents as well as they present a weak prognosis particularly in cardiovascular diseases. Yet, frailty is not only a set of physical deficits, but it also concerns psychological and social dimensions of human functioning. Hence, an approach to frailty should be multidimensional because such a concept more adequately reflects a functional degradation in the elderly. Frailty is usually associated with the impaired condition of circulatory system, and therefore, an identification of subclinical cardiovascular abnormalities is paramount in the frailty prevention and treatment. Another potential mechanism which may predispose to frailty is a dysfunction of the autonomic nervous system. This system plays a crucial role in the response to internal or external stressors such as diseases and activities of daily living. An impairment of the autonomic nervous system function may maintain or accelerate the frailty process.\n\nIn this scientific project, a comprehensive echocardiography will investigate cardiac function with a particular attention to features which typically change with age, like flow parameters and chambers sizes. The activity of the autonomic nervous system will be explored with the analysis of heart rate, blood pressure and respiratory signals. The study participants will also undergo routine medical examination and a number of additional tests, including: assessment of cognitive function, psychological condition, nutrition status, activities of daily living, and risk of falls. The study group will comprise community dwelling elderly individuals over the age of 65 years who get around by themselves. After 2 years, the participants will be re-examined for their frailty and independence status, as well as their survival will be checked with the National Health Found electronic system. The aim of this project is to seek for factors determining frailty and to explore the frailty impact on the elderly people survival. Particular attention will be paid to the multidimensional frailty which is a new concept of the functional decline in the elderly. In addition, the prevalence of different modes of frailty in Polish community will be investigated. The results of this research should help to establish preventative and therapeutic strategies against frailty.",[34,241,242,243,25,244,245,26],"Frailty Syndrome","Frail Elderly Syndrome","Fragility","Aging Problems","Aging Disorder",[34,247,248,249,250,251,25,252,253],"Physical Frailty","Cognitive Frailty","Social Frailty","Multidimensional Frailty","Elderly","Frail Scale","Tilburg Frailty Indicator","2020-08-14",{"date":256,"type":61},"2020-08-19",{"date":258,"type":61},"2017-09-02",{"date":260,"type":21},"2026-12",{"name":262,"class":96},"The Opole University of Technology"]